Building Biomedical Data Platforms That Scale Beyond a Single Program

Public health agencies and research consortia are under pressure to do more than stand up one successful data repository for one disease area. They need secure, extensible platforms that can support multiple programs, enable collaboration across institutions and create a durable foundation for advanced analytics and AI. When research infrastructure is built around a single study or a single disease, organizations often end up recreating the same capabilities again and again: data intake, de-identification, user access, metadata management, participant matching and analytics workflows. That slows discovery, increases cost and makes cross-study learning much harder than it should be.

A better model is a disease-agnostic biomedical data platform: one that is modular by design, standardized where it matters and flexible enough to adapt to new research priorities over time. Publicis Sapient’s work in biomedical informatics shows what that looks like in practice. From advancing centralized repositories and de-identified data sharing for NIH-supported Parkinson’s research to helping deliver BRICS, a web-based and extensible bioinformatics platform used across multiple federal programs and disease areas, the lesson is clear: the strongest research platforms are built for reuse, not just for one initiative.

Why single-program infrastructure reaches its limits

Biomedical research data is inherently complex. Clinical observations, genomic sequencing, imaging, biospecimens and patient-reported information often live in different systems, follow different standards and arrive from different institutions. In rare disease and multi-site research especially, fragmentation creates real barriers. Small patient populations are dispersed. Data capture methods vary. Privacy requirements complicate sharing. And without standardized structures, it becomes difficult to aggregate information, perform meta-analysis or follow participants longitudinally.

Traditional, partitioned approaches can also create duplication of effort. Research teams spend too much time locating, cleaning, translating and reconciling data instead of analyzing it. Agencies may invest heavily in one program only to discover that the architecture cannot easily support the next disease area, the next consortium or the next generation of analytical methods. That is why a platform mindset matters. Instead of building fixed-purpose systems, agencies can invest in reusable infrastructure that supports present-day research needs while remaining adaptable for future growth.

The core building blocks of a scalable biomedical research platform

1. Modular repositories and services. A scalable platform should not be a monolith. It should offer plug-and-play components that can be configured for different research programs without rebuilding the entire stack. In BRICS, modular capabilities such as data dictionaries, repositories, meta-study tools and imaging data submission allow programs to tailor the platform to their needs while staying on a common foundation. This kind of modularity makes it easier to onboard new disease areas, add capabilities incrementally and avoid expensive reinvention.

2. Standardized data dictionaries and harmonized capture. Cross-study analytics only work when data can be understood consistently. Standardized data dictionaries create a shared language for variables, formats and definitions across sites and studies. They reduce friction in data submission, improve quality and make downstream reuse far more practical. Publicis Sapient’s work in NIH-supported Parkinson’s research emphasized optimizing data acquisition standards and improving the standardization of data capture protocols, helping create a large harmonized dataset for broader research use.

3. Federated user management and controlled access. Research collaboration depends on making data available to the right people without sacrificing control. Robust user management, access controls and federated account models help agencies support broad participation across programs, institutions and disciplines. These capabilities are especially important when platforms serve multiple agencies or consortia with different governance needs. They also help platforms scale operationally, because onboarding users, managing permissions and enforcing policy become repeatable services rather than custom work for each program.

4. De-identification and privacy by design. Sensitive human subject data must be protected from the start. Scalable platforms treat privacy and compliance as design requirements, not afterthoughts. De-identification, role-based access and secure data-sharing workflows make it possible to enable meaningful research while protecting participants. In NIH-related work, Publicis Sapient helped provide more reliable and comprehensive de-identified datasets to researchers, improving efficiency in large-scale analysis while supporting best practices in medical research.

5. GUID-based participant matching. Longitudinal and cross-study research require a way to correlate participant data without exposing personally identifiable information. A Global Unique Identifier approach addresses this challenge directly. BRICS uses a GUID system that allows researchers to match participant records across studies securely, supporting longitudinal tracking, natural history research and data reuse without compromising privacy. For agencies designing future-ready platforms, this is a foundational capability, not an optional enhancement.

6. Support for multi-modal data. Modern biomedical discovery depends on more than clinical records alone. Platforms increasingly need to support clinical, genomic, imaging and patient-reported data in unified environments. The goal is not simply storage. It is making these data types easier to harmonize, query and analyze together. When agencies create a common digital foundation for multi-modal data, they enable richer biomarker discovery, stronger patient stratification, better clinical trial readiness and more valuable secondary analysis.

BRICS as a proof point for disease-agnostic scale

BRICS illustrates what reusable biomedical infrastructure can achieve when it is designed for extensibility from the outset. Developed in partnership with NIH and other federal agencies, the platform supports more than three million records representing nearly 100,000 subjects across more than 200 studies and 11 disease areas. It serves as the backbone for major programs including the Rare Diseases Registry Program, Federal Interagency Traumatic Brain Injury Research and the Parkinson’s Disease Biomarkers Program.

That breadth matters. It shows that research infrastructure does not need to be rebuilt disease by disease. With the right modular architecture, participant matching model, metadata framework and governance approach, one platform can support multiple scientific communities while allowing each to configure the capabilities it needs. This is especially valuable for public-sector organizations seeking to maximize funding impact, improve data reuse and respond quickly to emerging priorities.

From disease-specific success to platform blueprint

Publicis Sapient’s work with NIH-supported Parkinson’s research adds another practical lesson: centralized protocols and repositories can do more than streamline operations. They can change research output. By improving how data was captured, standardized, shared and analyzed, the program produced comprehensive clinical profiles for 1,599 qualifying study subjects, 1,469 whole genome sequencing samples and 3,538 processed RNA-sequence samples. The effort also contributed to a 300% increase in funded projects. Just as importantly, the work expanded into related disease research, demonstrating the value of building infrastructure that can extend beyond its initial scope.

For agencies and consortia, that is the real opportunity. A well-designed platform is not just a system of record. It is a system for growth. It helps teams launch new registries faster, connect studies more effectively, support rare disease and mainstream programs on the same foundation and create an environment where data becomes more valuable over time.

Preparing the foundation for future AI use cases

Many organizations are eager to apply AI to biomedical research, but AI is only as strong as the data foundation beneath it. Scalable use cases such as biomarker discovery, pattern recognition, patient clustering, advanced visualization and hypothesis generation depend on harmonized, governed and interoperable datasets. Agencies that invest first in modular architecture, standardized models, privacy controls and multi-modal integration are far better positioned to adopt machine learning and AI responsibly later.

That is why the most important AI decision may come before any model is built: choosing to create a platform that can support analytics and AI across programs rather than locking each initiative into its own isolated infrastructure.

Build once, extend often

Public health agencies and research consortia do not need more disconnected repositories. They need biomedical data platforms that are secure, extensible and designed to evolve. With modular repositories, standardized data dictionaries, federated user management, de-identification, GUID-based participant matching and support for multi-modal research data, organizations can create a reusable blueprint for discovery across disease areas.

That approach does more than reduce duplication. It enables cross-study analytics, strengthens collaboration, improves long-term sustainability and lays the groundwork for future AI-driven insight. For agencies looking to modernize research infrastructure, the path forward is not to build another silo. It is to build a platform that can grow with the science.